• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

• 페이스북 공유
• 트위터 공유

Personalized Depression Treatment

Traditional therapy and medication are not effective for a lot of patients suffering from depression. The individual approach to treatment could be the answer.

Cue is an intervention platform that converts sensor data collected from smartphones into personalised micro-interventions that improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their feature predictors and reveal distinct features that are able to change mood with time.

Predictors of Mood

Depression is among the leading causes of mental illness.1 Yet, only half of people suffering from the condition receive treatment1. To improve the outcomes, doctors must be able identify and treat patients most likely to respond to specific treatments.

The ability to tailor depression treatments is one way to do this. Using sensors on mobile phones, an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from the treatments they receive. With two grants awarded totaling more than $10 million, they will use these techniques to determine biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

The majority of research to the present has been focused on sociodemographic and clinical characteristics. These include factors that affect the demographics such as age, sex and education, clinical characteristics such as the severity of symptoms and comorbidities and biological markers such as neuroimaging and genetic variation.

While many of these aspects can be predicted by the information in medical records, very few studies have used longitudinal data to study predictors of mood in individuals. Many studies do not take into consideration the fact that moods vary significantly between individuals. Therefore, it is critical to develop methods that permit the identification of individual differences in mood predictors and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can identify distinct patterns of behavior and emotions that vary between individuals.

In addition to these modalities the team developed a machine-learning algorithm to model the dynamic factors that determine a person's depressed mood. The algorithm blends the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype was linked to CAT DI scores which is a psychometrically validated symptom severity scale. The correlation was weak, however (Pearson r = 0,08, P-value adjusted by BH 3.55 x 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is the most common cause of disability around the world1, but it is often misdiagnosed and untreated2. In addition an absence of effective interventions and stigma associated with depressive disorders prevent many people from seeking help.

To aid in the development of a personalized treatment, it is important to identify the factors that predict symptoms. The current methods for predicting symptoms rely heavily on clinical interviews, which are not reliable and only detect a few symptoms associated with depression.

Machine learning can enhance the accuracy of the diagnosis and treatment of depression by combining continuous digital behavioral patterns gathered from sensors on smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can provide continuous, high-resolution measurements as well as capture a variety of distinct behaviors and patterns that are difficult to capture using interviews.

The study comprised University of California Los Angeles students who had mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical care depending on their depression severity. Those with a score on the CAT-DI of 35 or 65 were given online support with an instructor and those with a score 75 were sent to in-person clinical care for psychotherapy.

Participants were asked a series of questions at the beginning of the study regarding their demographics and psychosocial characteristics. The questions included age, sex, and education and financial status, marital status as well as whether they divorced or not, their current suicidal thoughts, intent or attempts, and the frequency with which they consumed alcohol. The CAT-DI was used for assessing the severity of depression symptoms on a scale of 0-100. The CAT-DI assessment was conducted every two weeks for participants who received online support, and weekly for those who received in-person assistance.

Predictors of Treatment Response

Research is focused on individualized depression natural treatment for depression. Many studies are focused on finding predictors, which can aid clinicians in identifying the most effective medications for each person. Pharmacogenetics, for instance, uncovers genetic variations that affect how the body's metabolism reacts to drugs. This allows doctors to select the medications that are most likely to work best for each patient, reducing the time and effort in trials and errors, while avoid any adverse effects that could otherwise hinder progress.

Another promising approach is to build prediction models combining information from clinical studies and neural imaging data. These models can be used to identify the most effective combination of variables that is predictive of a particular outcome, like whether or not a particular medication will improve symptoms and mood. These models can be used to determine the patient's response to treatment, allowing doctors maximize the effectiveness.

A new generation uses machine learning techniques such as the supervised and classification algorithms such as regularized logistic regression, and tree-based methods to integrate the effects of several variables and improve predictive accuracy. These models have been demonstrated to be effective in predicting outcomes of treatment like the response to antidepressants. These methods are becoming more popular in psychiatry and could become the norm in the future treatment.

Research into depression's underlying mechanisms continues, as well as ML-based predictive models. Recent findings suggest that the disorder is linked with neural dysfunctions that affect specific circuits. This suggests that individual depression treatment will be focused on therapies that target these circuits to restore normal functioning.

Internet-based-based therapies can be a way to accomplish this. They can offer a more tailored and individualized experience for patients. One study found that a web-based program was more effective than standard treatment in reducing symptoms and ensuring an improved quality of life for patients with MDD. Additionally, a randomized controlled trial of a personalized treatment for depression treatment online demonstrated steady improvement and decreased side effects in a significant number of participants.

Predictors of adverse effects

A major obstacle in individualized depression treatment cbt treatment involves identifying and predicting which antidepressant medications will have the least amount of side effects or none at all. Many patients are prescribed various medications before finding a medication that is safe and effective. Pharmacogenetics offers a fascinating new method for an effective and precise approach to selecting antidepressant treatments.

Many predictors can be used to determine the best antidepressant to prescribe, including genetic variants, patient phenotypes (e.g., sex or ethnicity) and comorbidities. However, identifying the most reliable and accurate predictive factors for a specific treatment is likely to require randomized controlled trials of considerably larger samples than those that are typically part of clinical trials. This is due to the fact that the identification of interaction effects or moderators can be a lot more difficult in trials that take into account a single episode of treatment per patient instead of multiple sessions of treatment over a period of time.

Furthermore the prediction of a patient's response will likely require information about the severity of symptoms, comorbidities and the patient's personal experience of tolerability and effectiveness. There are currently only a few easily identifiable sociodemographic variables and clinical variables appear to be reliably related to response to MDD. These include age, gender and race/ethnicity, BMI, SES and the presence of alexithymia.

Many challenges remain when it comes to the use of pharmacogenetics for depression during pregnancy treatment treatment. First, a clear understanding of the genetic mechanisms is needed and an understanding of what constitutes a reliable predictor for treatment response. Additionally, ethical issues, such as privacy and the responsible use of personal genetic information, should be considered with care. Pharmacogenetics can eventually, reduce stigma surrounding mental health treatment and improve treatment outcomes. But, like any other psychiatric holistic Treatment for depression [https://Trade-britanica.trade/], careful consideration and implementation is required. At present, it's recommended to provide patients with a variety of medications for depression that are effective and encourage them to speak openly with their doctor.